株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

末梢血管ステント:医療機器のパイプライン評価

Peripheral Vascular Stents - Medical Devices Pipeline Assessment, 2016

発行 GlobalData 商品コード 223329
出版日 ページ情報 英文 213 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.56円で換算しております。
Back to Top
末梢血管ステント:医療機器のパイプライン評価 Peripheral Vascular Stents - Medical Devices Pipeline Assessment, 2016
出版日: 2016年12月01日 ページ情報: 英文 213 Pages
概要

当レポートでは、世界の末梢血管ステント市場における、主要なパイプライン製品 (医療機器) とその治験の進行状況について調査すると共に、製品特性の比較分析 (治験の進行段階別) や、主要企業のプロファイルおよび代表的製品、昨今の市場動静 (資本取引・事業提携など) といった情報を取りまとめてお届けいたします。

第1章 目次

第2章 イントロダクション

  • 末梢血管ステントの概要

第3章 現在治験中の製品

  • パイプライン製品:治験段階別
  • パイプライン製品:セグメント別
  • パイプライン製品:領域別
  • パイプライン製品:規制経路別
  • パイプライン製品:推定認証時期別
  • 現在進行中の治験

第4章 末梢血管ステント心臓:各企業で現在治験中のパイプライン製品

  • 末梢血管ステントの企業:治験段階別のパイプライン製品
  • 末梢血管ステント:治験段階別のパイプライン製品

第5章 末梢血管ステントの企業・製品の概要

  • 3D Biotek LLC
  • 480 Biomedical In
  • Abbott Vascular Inc.
  • Biotronik SE & Co KG
  • Boston Scientific Corp
  • C. R. Bard Inc
  • Cardiatis SA
  • Cook Medical Inc
  • Cordis Corp
  • Corinnova Inc
  • Cytograft Tissue Engineering Inc
  • Efferent Labs Inc
  • Electroformed Stents Inc
  • Elixir Medical Corp
  • Hexacath
  • InspireMD Inc
  • Intact Vascular, LLC
  • Lifetech Scientific (Shenzhen) Co., Ltd
  • LimFlow GmbH
  • Medinol Ltd
  • Medtronic plc
  • MicroVention, Inc.
  • Natec Medical Ltd
  • Nexeon MedSystems Inc
  • ニプロ
  • Northwestern University
  • NSVascular, Inc.
  • PeriTec Biosciences Ltd
  • Stron Medical
  • Synergy Flow Ltd
  • Taewoong Medical Co.,Ltd.
  • Tepha Inc
  • TissueGen Inc
  • University of Michigan
  • University of Texas Medical Branch at Galveston
  • Vascular Bioresorbable Technologies
  • Vascular Concepts Ltd
  • Veniti Inc
  • Veryan Medical Limited
  • VueKlar Cardiovascular Ltd
  • Xenogenics Corporation

第6章 末梢血管ステント市場:昨今の動向 (全77件)

第7章 提言

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDME0293EPD

GlobalData's Medical Devices sector report, "Peripheral Vascular Stents - Medical Devices Pipeline Assessment, 2016" provides an overview of Peripheral Vascular Stents currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Peripheral Vascular Stents pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Peripheral Vascular Stents under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Peripheral Vascular Stents and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Peripheral Vascular Stents under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Peripheral Vascular Stents Overview

3. Products under Development

  • 3.1. Peripheral Vascular Stents - Pipeline Products by Stage of Development
  • 3.2. Peripheral Vascular Stents - Pipeline Products by Segment
  • 3.3. Peripheral Vascular Stents - Pipeline Products by Territory
  • 3.4. Peripheral Vascular Stents - Pipeline Products by Regulatory Path
  • 3.5. Peripheral Vascular Stents - Pipeline Products by Estimated Approval Date
  • 3.6. Peripheral Vascular Stents - Ongoing Clinical Trials

4. Peripheral Vascular Stents - Pipeline Products under Development by Companies

  • 4.1. Peripheral Vascular Stents Companies - Pipeline Products by Stage of Development
  • 4.2. Peripheral Vascular Stents - Pipeline Products by Stage of Development

5. Peripheral Vascular Stents Companies and Product Overview

  • 5.1. 3D Biotek LLC Company Overview
  • 5.2. 480. Biomedical Inc Company Overview
  • 5.3. Abbott Vascular Inc. Company Overview
  • 5.4. Biotronik SE & Co KG Company Overview
  • 5.5. Boston Scientific Corp Company Overview
  • 5.6. C. R. Bard Inc Company Overview
  • 5.7. Cardiatis SA Company Overview
  • 5.8. Cook Medical Inc Company Overview
  • 5.9. Cordis Corp Company Overview
  • 5.10. Corinnova Inc Company Overview
  • 5.11. Cytograft Tissue Engineering Inc Company Overview
  • 5.12. Efferent Labs Inc Company Overview
  • 5.13. Electroformed Stents Inc Company Overview
  • 5.14. Elixir Medical Corp Company Overview
  • 5.15. Hexacath Company Overview
  • 5.16. InspireMD Inc Company Overview
  • 5.17. Intact Vascular, LLC Company Overview
  • 5.18. Lifetech Scientific (Shenzhen) Co., Ltd. Company Overview
  • 5.19. LimFlow GmbH Company Overview
  • 5.20. Medinol Ltd Company Overview
  • 5.21. Medtronic plc Company Overview
  • 5.22. MicroVention, Inc. Company Overview
  • 5.23. Natec Medical Ltd Company Overview
  • 5.24. Nexeon MedSystems Inc Company Overview
  • 5.25. Nipro Corp Company Overview
  • 5.26. Northwestern University Company Overview
  • 5.27. NSVascular, Inc. Company Overview
  • 5.28. PeriTec Biosciences Ltd Company Overview
  • 5.29. Stron Medical Company Overview
  • 5.30. Synergy Flow Ltd Company Overview
  • 5.31. Taewoong Medical Co.,Ltd. Company Overview
  • 5.32. Tepha Inc Company Overview
  • 5.33. TissueGen Inc Company Overview
  • 5.34. University of Michigan Company Overview
  • 5.35. University of Texas Medical Branch at Galveston Company Overview
  • 5.36. Vascular Bioresorbable Technologies Company Overview
  • 5.37. Vascular Concepts Ltd Company Overview
  • 5.38. Veniti Inc Company Overview
  • 5.39. Veryan Medical Limited Company Overview
  • 5.40. VueKlar Cardiovascular Ltd Company Overview
  • 5.41. Xenogenics Corporation Company Overview

6. Peripheral Vascular Stents- Recent Developments

  • 6.1. Nov 22, 2016: Medtronic Reports Second Quarter Financial Results
  • 6.2. Nov 21, 2016: VEITHsymposium 2016: BIOTRONIK Showcases Positive Results for Pulsar-18 Stent in the SFA
  • 6.3. Nov 18, 2016: Abbott Labs Prices Public Offering of 4.75% Notes due 2036 for USD1.7 Billion
  • 6.4. Nov 16, 2016: Medtronic Releases FY16 Integrated Performance Report
  • 6.5. Nov 15, 2016: Final Patient Enrolled for Iliofemoral Venous Stent Study
  • 6.6. Nov 15, 2016: LimFlow Receives CE Mark for Purely Percutaneous Critical Limb Ischemia Technology Designed to Restore Perfusion for "No Option" Patients
  • 6.7. Nov 15, 2016: CEVA to work with Medtronic for distribution facility construction
  • 6.8. Nov 14, 2016: AngioDynamics Prices Public Offering of Shares for USD32 Million
  • 6.9. Nov 14, 2016: InspireMD Reports Financial Results for the Third Quarter Ended September 30, 2016
  • 6.10. Nov 14, 2016: Neovasc Reports Third Quarter Results for 2016
  • 6.11. Nov 09, 2016: AngioDynamics Announces Addition of New Board Members
  • 6.12. Oct 31, 2016: FDA Approves TOBA II BTK Pivotal IDE Clinical Study
  • 6.13. Oct 27, 2016: CONMED Announces Third Quarter 2016 Financial Results
  • 6.14. Oct 26, 2016: Boston Scientific Announces Results For Third Quarter 2016
  • 6.15. Oct 26, 2016: Merit Medical Reports Sales Up 15.3% for the Quarter Ended September 30, 2016
  • 6.16. Oct 25, 2016: Edwards Lifesciences Reports Third Quarter Results
  • 6.17. Oct 25, 2016: Bard Announces Third Quarter Results
  • 6.18. Oct 24, 2016: Boston Scientific announced key Presentations on Eluvia Drug-Eluting Vascular Stent System at Transcatheter Cardiovascular Therapeutics 2016
  • 6.19. Oct 20, 2016: Akesys Medical and Elixir Medical Announce First Human Implant of the PRAVA Bioresorbable Scaffold for Peripheral Vascular Disease
  • 6.20. Oct 19, 2016: Abbott Reports Third-Quarter 2016 Results
  • 6.21. Oct 18, 2016: LimFlow Names Daniel Rose as Chief Executive Officer
  • 6.22. Oct 11, 2016: Tepha Enters into Agreement with Metabolix
  • 6.23. Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer
  • 6.24. Oct 05, 2016: AngioDynamics Reports Fiscal 2017 First Quarter Results
  • 6.25. Sep 27, 2016: Boston Scientific Acquires EndoChoice for USD210 Million in Tender Offer
  • 6.26. Sep 15, 2016: STENTYS Reports 2016 First-Half Results
  • 6.27. Sep 15, 2016: Medtronic Names Mark Ploof Senior Vice President of Global Operations and Business Services
  • 6.28. Sep 08, 2016: VENITI Raises USD25 Million in Series D Equity Financing
  • 6.29. Sep 07, 2016: GORE VIABAHN Endoprosthesis Marks 20 Years of Proven Performance
  • 6.30. Sep 07, 2016: InspireMD Appoints Thomas Kester to Board of Directors
  • 6.31. Aug 31, 2016: Cook Medical Names Jean-Marc Creissel Vice President of Operations in Greater China
  • 6.32. Aug 25, 2016: Medtronic Reports First Quarter Financial Results
  • 6.33. Aug 09, 2016: InspireMD Reports Financial Results for the Second Quarter Ended June 30, 2016
  • 6.34. Aug 09, 2016: Neovasc Reports Second Quarter Results for 2016
  • 6.35. Aug 03, 2016: EndoChoice Announces Second Quarter 2016 Financial Results
  • 6.36. Aug 02, 2016: GORE TIGRIS Vascular Stent Gains FDA Approval for Treatment of Peripheral Artery Disease
  • 6.37. Jul 28, 2016: Boston Scientific Announces Results For Second Quarter 2016
  • 6.38. Jul 27, 2016: Merit Medical Reports Sales Up 9.4% for the Quarter Ended June 30, 2016
  • 6.39. Jul 27, 2016: CONMED Announces Second Quarter 2016 Financial Results
  • 6.40. Jul 26, 2016: Merit Medical Announces Appointment of New Director
  • 6.41. Jul 26, 2016: Edwards Lifesciences Reports Second Quarter Results
  • 6.42. Jul 26, 2016: Bard Announces Second Quarter Results
  • 6.43. Jul 25, 2016: AngioDynamics Appoints Michael C. Greiner as New Chief Financial Officer
  • 6.44. Jul 21, 2016: Svelte Medical Systems Raises USD4 Million in Venture Financing
  • 6.45. Jul 20, 2016: Abbott Reports Second-Quarter 2016 Results
  • 6.46. Jul 13, 2016: Boston Scientific Elects Yoshiaki Fujimori to Board of Directors
  • 6.47. Jul 13, 2016: AngioDynamics Reports Fiscal 2016 Fourth Quarter and Full Year Results
  • 6.48. Jul 12, 2016: STENTYS: 41% Increase in Revenues in the Second Quarter of 2016
  • 6.49. Jul 05, 2016: Neovasc Receives NASDAQ Notification Regarding Minimum Bid Requirements
  • 6.50. Jul 04, 2016: STENTYS: Appointment of Cardiolovascular Device Veteran as New CEO
  • 6.51. Jun 30, 2016: NuVasive Agrees to Settle Patent Litigation With Medtronic
  • 6.52. Jun 29, 2016: InspireMD Raises USD14.6 Million in Public Offering of Preferred Stock and Warrants
  • 6.53. Jun 28, 2016: GORE VIABAHN Endoprosthesis Found to Provide Superior Patency and Reduced Interventions Versus Balloon Angioplasty Alone for Challenging AV Access Cases
  • 6.54. Jun 20, 2016: VENITI Announces 1,000th Patient Treated With VICI VENOUS STENT
  • 6.55. Jun 08, 2016: Boston Scientific Announces Restructuring Program to Support Long-Term Growth and Innovation
  • 6.56. Jun 06, 2016: Medtronic Outlines Future Growth Vision at Investor Day
  • 6.57. May 31, 2016: Medtronic Reports Fourth Quarter and Fiscal Year 2016 Financial Results
  • 6.58. May 13, 2016: Boston Scientific Announces Presentation of Eluvia stent system at EuroPCR 2016
  • 6.59. May 10, 2016: InspireMD Reports Financial Results for the First Quarter Ended March 31, 2016
  • 6.60. May 04, 2016: Positive Twelve-Month Tack Optimized Balloon Angioplasty Below-the-Knee (TOBA-BTK) Results Presented at SCAI 2016
  • 6.61. May 02, 2016: A.G. Schneiderman Announces $306 Million National Settlement With Olympus
  • 6.62. Apr 29, 2016: Neovasc Reports First Quarter Results for 2016
  • 6.63. Apr 21, 2016: VENITI Completes First Use Of VICI VERTO VENOUS STENT, Novel Venous Stent System
  • 6.64. Apr 20, 2016: Abbott Reports First-Quarter 2016 Results
  • 6.65. Apr 13, 2016: STENTYS Reports 38% Increase in Revenues in First Quarter 2016
  • 6.66. Apr 07, 2016: AngioDynamics Reports Fiscal 2016 Third Quarter Results
  • 6.67. Apr 04, 2016: AngioDynamics Appoints James C. Clemmer as New President and Chief Executive Officer
  • 6.68. Mar 29, 2016: Neovasc Announces Results for the Fourth Quarter and Fiscal Year 2015
  • 6.69. Mar 16, 2016: STENTYS Reports 2015 Annual Results
  • 6.70. Mar 15, 2016: InspireMD Raises USD0.6 Million in Private Placement of Shares and Warrants
  • 6.71. Mar 04, 2016: Palmaz Scientific Announces Chapter 11 Filing; Seeks Prospective Buyers for Its Breakthrough Technology
  • 6.72. Feb 22, 2016: Boston Scientific Receives CE Mark For Eluvia Drug-Eluting Vascular Stent And Announces Initiation Of New Clinical Trial
  • 6.73. Feb 12, 2016: Stentys Raises USD14.3 Million in Rights Offering of Shares
  • 6.74. Feb 08, 2016: STENTYS initiates the Commercialization of the first Self-Expanding Drug-Eluting stent for the Below-The-Knee Indication
  • 6.75. Jan 26, 2016: Positive Six-Month Tack Optimized Balloon Angioplasty Below-the-Knee (TOBA-BTK) Results Presented at LINC 2016
  • 6.76. Jan 13, 2016: STENTYS Reports 81% Year-over-Year Growth in Fourth-Quarter 2015 Revenues
  • 6.77. Jan 07, 2016: AngioDynamics Reports Fiscal 2016 Second Quarter Results

7. Appendix

  • 7.1. Methodology
  • 7.2. About GlobalData
  • 7.3. Contact Us
  • 7.4. Disclaimer

List of Tables

  • Table 1: Peripheral Vascular Stents - Pipeline Products by Stage of Development
  • Table 2: Peripheral Vascular Stents - Pipeline Products by Segment
  • Table 3: Peripheral Vascular Stents - Pipeline Products by Territory
  • Table 4: Peripheral Vascular Stents - Pipeline Products by Regulatory Path
  • Table 5: Peripheral Vascular Stents - Pipeline Products by Estimated Approval Date
  • Table 6: Peripheral Vascular Stents - Ongoing Clinical Trials
  • Table 7: Peripheral Vascular Stents Companies - Pipeline Products by Stage of Development
  • Table 8: Peripheral Vascular Stents - Pipeline Products by Stage of Development
  • Table 9: 3D Biotek LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 10: Bioresorbable Drug Eluting Peripheral Polymer Stent - Product Status
  • Table 11: Bioresorbable Drug Eluting Peripheral Polymer Stent - Product Description
  • Table 12: 480 Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 13: Stanza Bioresorbable Pediatric Scaffold - Product Status
  • Table 14: Stanza Bioresorbable Pediatric Scaffold - Product Description
  • Table 15: Stanza Bioresorbable Self-Expanding Scaffold - Product Status
  • Table 16: Stanza Bioresorbable Self-Expanding Scaffold - Product Description
  • Table 17: 480 Biomedical Inc - Ongoing Clinical Trials Overview
  • Table 18: Stanza Bioresorbable Self-Expanding Scaffold - An Evaluation of the 480 Biomedical STANZA Drug-Eluting Resorbable Scaffold (DRS) System in the Treatment of de Novo SFA Lesions
  • Table 19: Abbott Vascular Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 20: ESPRIT Bioresorbable Vascular Scaffold - Product Status
  • Table 21: ESPRIT Bioresorbable Vascular Scaffold - Product Description
  • Table 22: Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview
  • Table 23: Astron Pulsar Self Expanding Peripheral Stent - Product Status
  • Table 24: Astron Pulsar Self Expanding Peripheral Stent - Product Description
  • Table 25: Pulsar-18 Self Expanding Stent - Product Status
  • Table 26: Pulsar-18 Self Expanding Stent - Product Description
  • Table 27: Biotronik SE & Co KG - Ongoing Clinical Trials Overview
  • Table 28: Astron Pulsar Self Expanding Peripheral Stent - The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar-18 Stents (BIOFLEX-I Europe)
  • Table 29: Pulsar-18 Self Expanding Stent - BIOFLEX PEACE All-comers Trial
  • Table 30: Pulsar-18 Self Expanding Stent - Physician-Initiated Trial Investigating the Efficacy of Endovascular Treatment of Femoropopliteal Arterial Stenotic Disease with the Biotronik Passeo-18 Lux Drug Releasing Balloon and the Biotronik Pulsar-18 Stent (Comparing with 4EVER Trial Results) (BIOLUX 4EVER)
  • Table 31: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
  • Table 32: Cobalt-Chromium Iliac Balloon Expandable Stent - Product Status
  • Table 33: Cobalt-Chromium Iliac Balloon Expandable Stent - Product Description
  • Table 34: Eluvia Drug-Eluting Vascular Stent System - Product Status
  • Table 35: Eluvia Drug-Eluting Vascular Stent System - Product Description
  • Table 36: Gallbladder Drainage System - Product Status
  • Table 37: Gallbladder Drainage System - Product Description
  • Table 38: Wallstent RP Endoprosthesis - Venous Outflow Obstruction - Product Status
  • Table 39: Wallstent RP Endoprosthesis - Venous Outflow Obstruction - Product Description
  • Table 40: Boston Scientific Corp - Ongoing Clinical Trials Overview
  • Table 41: Eluvia Drug-Eluting Vascular Stent System - A Randomized Trial Comparing the ELUVIA Drug-eluting Stent Versus Bare Metal Self-expanding Nitinol Stents in the Treatment of Superficial Femoral and/or Proximal Popliteal Arteries
  • Table 42: Eluvia Drug-Eluting Vascular Stent System - A Randomized Trial Comparing the ELUVIA Drug-eluting Stent Versus Zilver PTX Stent for Treatment of Superficial Femoral and/or Proximal Popliteal Arteries
  • Table 43: Eluvia Drug-Eluting Vascular Stent System - Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project with Boston Scientific's Innova Drug Eluting Stent
  • Table 44: Wallstent RP Endoprosthesis - Venous Outflow Obstruction - Sinai Vein Stent Registry
  • Table 45: C. R. Bard Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 46: VENOVO Venous Stent - Product Status
  • Table 47: VENOVO Venous Stent - Product Description
  • Table 48: Cardiatis SA Pipeline Products & Ongoing Clinical Trials Overview
  • Table 49: Cardiatis FluidSmart 3D Stent - Product Status
  • Table 50: Cardiatis FluidSmart 3D Stent - Product Description
  • Table 51: Cook Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 52: Evolution Biliary Stent System-Partially Covered - Product Status
  • Table 53: Evolution Biliary Stent System-Partially Covered - Product Description
  • Table 54: Evolution Esophageal Stent System-Fully Covered - Product Status
  • Table 55: Evolution Esophageal Stent System-Fully Covered - Product Description
  • Table 56: Zenith Connection Endovascular Covered Stent - Product Status
  • Table 57: Zenith Connection Endovascular Covered Stent - Product Description
  • Table 58: Zenith Helical Branch Iliac Endovascular Graft - Product Status
  • Table 59: Zenith Helical Branch Iliac Endovascular Graft - Product Description
  • Table 60: ZILVER PTX Drug Eluting Peripheral Stent - Product Status
  • Table 61: ZILVER PTX Drug Eluting Peripheral Stent - Product Description
  • Table 62: Zilver Vena Venous Self-Expanding Stent - Product Status
  • Table 63: Zilver Vena Venous Self-Expanding Stent - Product Description
  • Table 64: Cook Medical Inc - Ongoing Clinical Trials Overview
  • Table 65: ZILVER PTX Drug Eluting Peripheral Stent - A Randomized Trial Comparing the ELUVIA Drug-eluting Stent Versus Zilver PTX Stent for Treatment of Superficial Femoral and/or Proximal Popliteal Arteries
  • Table 66: ZILVER PTX Drug Eluting Peripheral Stent - Bare Metal Stent Versus Paclitaxel Eluting Stent in the Setting of Primary Stenting of Intermediate Length Femoropopliteal Lesions
  • Table 67: ZILVER PTX Drug Eluting Peripheral Stent - Comparison of the Primary Long Versus Short Coverage with Drug-Eluting Stents for Long Femoropopliteal Artery Disease (PARADE II): Investigator-initiated Clinical Study
  • Table 68: ZILVER PTX Drug Eluting Peripheral Stent - Drug Eluting Stent for the Management of Peripheral Arterial Disease of the SFA (DESPERADO-SFA Study)
  • Table 69: ZILVER PTX Drug Eluting Peripheral Stent - Evaluation of the Zilver PTX Drug-eluting Peripheral Stent for Treatment of Lesions of the Above-the-knee Femoropopliteal Artery
  • Table 70: ZILVER PTX Drug Eluting Peripheral Stent - Paclitaxel-coated Peripheral Stents Used in the Treatment of Femoropopliteal Stenoses
  • Table 71: ZILVER PTX Drug Eluting Peripheral Stent - The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery for the Treatment The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery of Femoropopliteal TASC C&D Lesions (ZILVERPASS)
  • Table 72: ZILVER PTX Drug Eluting Peripheral Stent - Zilver PTX Drug-eluting Peripheral Stent Post-approval Study
  • Table 73: ZILVER PTX Drug Eluting Peripheral Stent - Zilver PTX Post-market Surveillance Study of Paclitaxel-eluting Stents for Treating Femoropopliteal Artery Disease in Japan
  • Table 74: Zilver Vena Venous Self-Expanding Stent - Evaluation of the Zilver Vena Venous Stent in the Treatment of Symptomatic Iliofemoral Venous Outflow Obstruction
  • Table 75: Evolution Esophageal Stent System-Fully Covered - Clinical Investigation to Evaluate Removal of the Evolution Esophageal Stent - Fully Covered
  • Table 76: Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview
  • Table 77: FlexStent Femoropopliteal Self Expanding Stent System - SFA - Product Status
  • Table 78: FlexStent Femoropopliteal Self Expanding Stent System - SFA - Product Description
  • Table 79: FlexStent Self Expanding Below-The-Knee Venous Stent System - Product Status
  • Table 80: FlexStent Self Expanding Below-The-Knee Venous Stent System - Product Description
  • Table 81: FlexStent Self Expanding Venous Stent System - Product Status
  • Table 82: FlexStent Self Expanding Venous Stent System - Product Description
  • Table 83: Tibial SE FlexStent - Product Status
  • Table 84: Tibial SE FlexStent - Product Description
  • Table 85: Cordis Corp - Ongoing Clinical Trials Overview
  • Table 86: FlexStent Femoropopliteal Self Expanding Stent System - SFA - Evaluation of Safety and Efficacy of the FlexStent Femoropopliteal Self-expanding Stent System Study
  • Table 87: Corinnova Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 88: Hybrid Dynamic Stent - Product Status
  • Table 89: Hybrid Dynamic Stent - Product Description
  • Table 90: Cytograft Tissue Engineering Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 91: LifeJacket Stent Graft - Peripheral - Product Status
  • Table 92: LifeJacket Stent Graft - Peripheral - Product Description
  • Table 93: Efferent Labs Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 94: RTI-LICD Plexisense - Product Status
  • Table 95: RTI-LICD Plexisense - Product Description
  • Table 96: Electroformed Stents Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 97: Helical Stent - Product Status
  • Table 98: Helical Stent - Product Description
  • Table 99: Patch Stent - Product Status
  • Table 100: Patch Stent - Product Description
  • Table 101: Pleated Stent - Product Status
  • Table 102: Pleated Stent - Product Description
  • Table 103: Elixir Medical Corp Pipeline Products & Ongoing Clinical Trials Overview
  • Table 104: PRAVA Bioresorbable Scaffold - Product Status
  • Table 105: PRAVA Bioresorbable Scaffold - Product Description
  • Table 106: Elixir Medical Corp - Ongoing Clinical Trials Overview
  • Table 107: PRAVA Bioresorbable Scaffold - Drug Eluting Scaffold with an Absorbable Platform for Primary Lower Extremity Arterial Revascularization (DESappear Study)
  • Table 108: Hexacath Pipeline Products & Ongoing Clinical Trials Overview
  • Table 109: HELIOS LD Peripheral Balloon Expandable Bio Active Stent - Product Status
  • Table 110: HELIOS LD Peripheral Balloon Expandable Bio Active Stent - Product Description
  • Table 111: InspireMD Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 112: PVGuard Peripheral - Product Status
  • Table 113: PVGuard Peripheral - Product Description
  • Table 114: Intact Vascular, LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 115: Tack Endovascular System - BTK - Product Status
  • Table 116: Tack Endovascular System - BTK - Product Description
  • Table 117: Intact Vascular, LLC - Ongoing Clinical Trials Overview
  • Table 118: Tack Endovascular System - BTK - Prospective, Multicenter Tack Optimized Balloon Angioplasty below the Knee (TOBA - BTK) Study for Infrapopliteal Arteries Using the Tack-it Endovascular System
  • Table 119: Tack Endovascular System - BTK - Tack Optimized Balloon Angioplasty Study for the below the Knee Arteries Using the Tack Endovascular System
  • Table 120: Lifetech Scientific (Shenzhen) Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 121: Peripheral Bare Stent - Product Status
  • Table 122: Peripheral Bare Stent - Product Description
  • Table 123: Peripheral Cover Stent - Product Status
  • Table 124: Peripheral Cover Stent - Product Description
  • Table 125: LimFlow GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • Table 126: LimFlow Stent Graft System - Product Status
  • Table 127: LimFlow Stent Graft System - Product Description
  • Table 128: Medinol Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 129: ChampioNIR - Product Status
  • Table 130: ChampioNIR - Product Description
  • Table 131: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 132: Maris - Product Status
  • Table 133: Maris - Product Description
  • Table 134: MicroVention, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 135: CASPER Carotid Stent - Product Status
  • Table 136: CASPER Carotid Stent - Product Description
  • Table 137: Natec Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 138: Marina - Product Status
  • Table 139: Marina - Product Description
  • Table 140: Nexeon MedSystems Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 141: CITATION Peripheral Stent System - Product Status
  • Table 142: CITATION Peripheral Stent System - Product Description
  • Table 143: Nipro Corp Pipeline Products & Ongoing Clinical Trials Overview
  • Table 144: Peripheral Stent - Product Status
  • Table 145: Peripheral Stent - Product Description

List of Figures

  • Figure 1: Peripheral Vascular Stents - Pipeline Products by Stage of Development
  • Figure 2: Peripheral Vascular Stents - Pipeline Products by Segment
  • Figure 3: Peripheral Vascular Stents - Pipeline Products by Territory
  • Figure 4: Peripheral Vascular Stents - Pipeline Products by Regulatory Path
  • Figure 5: Peripheral Vascular Stents - Pipeline Products by Estimated Approval Date
  • Figure 6: Peripheral Vascular Stents - Ongoing Clinical Trials
Back to Top